CTX310's ANGPTL3 Targeting Mechanism and the Innovation of In Vivo Gene Editing

CRISPR Therapeutics (CRISPR Therapeutics, CRSP) has officially commenced the Phase 1 clinical trial (NCT07491172) for CTX310, an in vivo gene editing therapy based on lipid nanoparticle (LNP) delivery technology. CTX310 works by permanently knocking out (Loss-of-Function) the angiopoietin-like protein 3 (ANGPTL3) gene in liver cells, simultaneously reducing levels of low-density lipoprotein cholesterol (LDL-C) and triglycerides in the blood. Following the success of Casgevy, an ex vivo therapy, this represents a significant expansion of its technological versatility into in vivo gene editing pipelines targeting liver diseases. It is expected to revolutionize the treatment paradigm for metabolic diseases, potentially requiring only a single intravenous administration for lifelong treatment.

Unmet Needs of Patients with Refractory Dyslipidemia and Clinical Objectives

This Phase 1 clinical trial is being conducted on patients with refractory dyslipidemia, who do not respond to conventional high-dose statin or PCSK9 inhibitor therapy. Patients with homozygous familial hypercholesterolemia (HoFH) or severe hypertriglyceridemia (sHTG) have difficulty achieving target blood lipid levels with existing drugs, leaving them continuously exposed to the risk of atherosclerotic cardiovascular disease (ASCVD). The clinical trial will focus on verifying the safety and tolerability of CTX310 through a dose-escalation phase. It will be a crucial test to confirm not only the short-term lipid-lowering effect but also the long-term sustainability of reduced ANGPTL3 protein levels in the blood.

Global Dyslipidemia Market Landscape and Differentiated Competitiveness

The global market for dyslipidemia treatments is expected to grow to approximately $22 billion (USD 22B) by 2030, making it a major therapeutic area. Currently, Regeneron's antibody therapy Evkeeza (evinacumab) and Arrowhead's RNAi therapy Zodasiran are targeting the ANGPTL3 pathway. However, these existing drugs require periodic repeated administration, while CTX310 offers a one-and-done treatment approach by permanently correcting the gene with a single administration. By providing near-curative treatment convenience, it has established a technological foundation to gain overwhelming commercial advantages over competing antibody and RNA therapies.

Expansion into Metabolic Diseases and Pipeline Value Re-rating

This trial marks a turning point, signaling that CRISPR Therapeutics' gene editing platform, previously limited to rare blood disorders, has entered the large market of chronic metabolic diseases. Following the approval of Casgevy, the company is not only a single-gene disease treatment provider but is also expanding into the much larger metabolic disease field. Together with Verve Therapeutics' VERV-201, a competitive landscape has emerged, vying for leadership in the in vivo liver-targeted gene editing market. If excellent safety profiles are demonstrated in the Phase 1 trial, a structural re-rating of the company's value is expected.